Gamma-hydroxybutyrate (GHB), often referred to as “liquid ecstasy,” is emerging as a significant public health concern across parts of England, with rising reports of addiction, overdoses, and related harms. Originally developed in the 1960s as a surgical anesthetic, GHB re-entered public awareness as a bodybuilding supplement in the 1980s before becoming popular as a recreational drug within rave and club scenes. Now, its use is spreading rapidly among diverse social groups, including students, young professionals, and working adults.
GHB is a colourless, odourless liquid that induces euphoria and increased confidence before sedative effects take hold. Its affordability, easily concealed form, and perceived lack of hangover symptoms contribute to its growing appeal. Users can purchase it in small millilitre doses, with many citing its economic advantages over alcohol for nightlife use. However, the drug carries significant risks, as the margin between a recreational dose and a dangerous one is narrow. Mixing GHB with alcohol or other depressants further amplifies these dangers.
Recent accounts from users and healthcare professionals highlight the drug’s potential for severe harm. One 21-year-old woman from Lancashire described how recreational use quickly escalated to regular consumption, culminating in a suspected overdose and a drug-facilitated sexual assault. Despite not reporting the incident to authorities due to concerns about professional repercussions, she sought medical care and counseling. Her case underscores how GHB’s undetectable nature in routine drug screening and ease of concealment complicate detection and prevention efforts.
Mental health experts working in Lancashire report a sharp increase in GHB-related cases. Steve Pope, a counsellor specialized in addiction treatment, noted a fourfold rise in cases over six months, with GHB dependency rivaling that of alcohol and ketamine. Withdrawal from GHB can involve severe symptoms such as anxiety, hallucinations, psychosis, and delirium, often requiring medical supervision and the use of medications like diazepam to manage symptoms. The drug’s addictive potential is exacerbated by compulsive redosing, a behavior rarely seen with other substances, complicating recovery efforts.
Incidents of GHB overdose resulting in respiratory depression, brain damage, and death have been documented, with official figures indicating 30 deaths linked to GHB poisoning in 2024/25 in England. However, experts caution these numbers may underestimate the problem due to limited testing and the drug’s stealthy nature.
Cases from different regions reflect the breadth of the issue. A 19-year-old apprentice engineer nearly died from an overdose after unknowingly consuming a usual dose, while a 31-year-old theatre technician’s dependency rapidly escalated, culminating in severe withdrawal symptoms and a supervised detoxification. Another young university student experienced unconsciousness shortly after ingesting GHB once, highlighting the unpredictable dangers even in initial use.
Law enforcement has intensified responses to GHB supply chains, exemplified by a recent Metropolitan Police seizure of over 2,000 litres of gamma-butyrolactone (GBL), the chemical precursor to GHB. The British government reclassified GHB from a Class C to a Class B drug in 2022 amid concerns about its involvement in drug-facilitated sexual assaults.
Researchers and harm-reduction advocates emphasize the urgency of addressing the issue. Professor Fiona Measham, chair in criminology at the University of Liverpool, points to GHB’s rapid addictive potential and widespread use across social strata. The drug’s initial reputation as a safer alternative to substances like ketamine—often associated with bladder damage—has contributed to its popularity.
Healthcare professionals warn that GHB’s effects on judgment, memory, and physical coordination render users particularly vulnerable to exploitation and serious injury. The drug’s ability to incapacitate quickly makes it a high-risk substance, with life-threatening consequences from small dosing errors.
As cases continue to rise, specialists stress the need for increased awareness, better testing protocols, and accessible treatment options. While some users manage to recover with support, many others remain at risk of significant harm, underscoring the growing challenge posed by GHB within communities nationwide.